Compound details
Speedoside
| Compound ID | CDAMM01802 |
|---|---|
| Common name | Speedoside | IUPAC name | [2-(hydroxymethyl)-10-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,9-dioxatricyclo[4.4.0.02,4]dec-7-en-5-yl] 3-[3-hydroxy-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-enoate |
| Molecular formula | C30H38O18 |
| Retention time | 15.35 |
|---|---|
| Adduct | [M+Na]+ |
| Actual mz | 709.186 | Theoretical mz | 709.195 |
| Error | 13.42 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 6.1675 |
| Inchi key | ANEVGLDJVAGIAL-XIZYATIWNA-N |
|---|---|
| Smiles | O=C(OC1C2OC2(CO)C3C(OC=CC13)OC4OC(CO)C(O)C(O)C4O)C=CC5=CC=C(OC6OC(CO)C(O)C(O)C6O)C(O)=C5 |
| Superclass | Organic oxygen compounds |
| Class | Organooxygen compounds |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| O43570 | CA12 | Carbonic anhydrase XII | T16987 | SEA |
| P15692 | VEGFA | Vascular endothelial growth factor A | T20761 | SEA |
| P05230 | FGF1 | Acidic fibroblast growth factor | T18639 | SEA |
| P09038 | FGF2 | Basic fibroblast growth factor | T31621 | SEA |
| P52789 | HK2 | Hexokinase type II | T96685 | SEA |
| P60568 | IL2 | Interleukin-2 | T61698 | SEA |
| P14679 | TYR | Tyrosinase | T97035 | SEA |
| P20916 | MAG | Myelin-associated glycoprotein (by homology) | T95286 | SEA |
| Q9NZ08 | ERAP1 | Endoplasmic reticulum aminopeptidase 1 | T72849 | SEA |
| O43826 | SLC37A4 | Glucose-6-phosphate translocase | T47306 | SEA |
| P30837 | ALDH1B1 | Acetaldehyde dehydrogenase | T99641 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T16987 | DI0046 | Bacterial infection | [ICD-11: 1A00-1C4Z] | O43570 | CA12 |
| T16987 | DI0372 | Seborrhoeic dermatitis | [ICD-11: EA81] | O43570 | CA12 |
| T20761 | DI0095 | Colorectal cancer | [ICD-11: 2B91] | P15692 | VEGFA |
| T20761 | DI0365 | Retinopathy | [ICD-11: 9B71] | P15692 | VEGFA |
| T20761 | DI0430 | Vascular system developmental anomaly | [ICD-11: LA90] | P15692 | VEGFA |
| T18639 | DI0081 | Chronic arterial occlusive disease | [ICD-11: BD4Z] | P05230 | FGF1 |
| T18639 | DI0102 | Coronary atherosclerosis | [ICD-11: BA52] | P05230 | FGF1 |
| T31621 | DI0005 | Acne vulgaris | [ICD-11: ED80] | P09038 | FGF2 |
| T96685 | DI0133 | Epidermal dysplasias | [ICD-11: EK90] | P52789 | HK2 |
| T61698 | DI0275 | Multiple sclerosis | [ICD-11: 8A40] | P60568 | IL2 |
| T61698 | DI0361 | Renal cell carcinoma | [ICD-11: 2C90] | P60568 | IL2 |
| T97035 | DI0007 | Acquired hypermelanosis | [ICD-11: ED60] | P14679 | TYR |
| T97035 | DI0008 | Acquired hypomelanotic disorder | [ICD-11: ED63] | P14679 | TYR |
| T95286 | DI0219 | Ischaemic/haemorrhagic stroke | [ICD-11: 8B20] | P20916 | MAG |
| T99641 | DI0396 | Substance abuse | [ICD-11: 6C40] | P30837 | ALDH1B1 |